Statement: Cohort 2 of the primary trial receive a higher dose of Ixabepilone than cohort 1, but the same dose of Epirubicin.
Primary_evidence: INTERVENTION 1:    Ixabepilone 25 mg^m2 + Epirubicin 75 mg^m2   Participants received 25 mg/m^2 Ixabepilone as a 3-hour IV infusion following a 3- to 5-minute IV infusion of 75 mg/m^2 epirubicin every 21 days. INTERVENTION 2:    Ixabepilone 30 mg^m2 + Epirubicin 75 mg^m2   Participants received 30 mg/m^2 Ixabepilone as a 3-hour IV infusion following a 3- to 5-minute IV infusion of 75 mg/m^2 epirubicin every 21 days.